Many patients don't have a plan for returning to work. You can help them make a plan and adapt to changes along the way. Do you know how to assess for gut GVHD? This article covers assessment, pathobiology, and staging. In patients with GVHD, some forms of grief are expected and accepted, yet others go unrecognized. Using these 3 strategies, you can build your resiliency to benefit yourself and your patients. Continuous intravenous tacrolimus administration can be logistically challenging. Can intermittent dosing work as well? Vascular access events caused most patients to discontinue treatment. Does catheter type affect event frequency? Can extracorporeal photopheresis treat acute graft-versus-host disease when the disease has become steroid dependent? The accepted belief is that late-onset acute GVHD is less severe, but one study demonstrated the opposite. Different radiotherapy doses in allogeneic HCT conditioning had no apparent impact on the rate of acute GVHD. Authors observed that ocular graft-versus-host disease usually developed after a history of systemic disease. A study found fecal microbiome dysbiosis accompanied the onset of gastrointestinal graft-versus-host disease. BCG vaccination at birth was associated with increased risk of acute GVHD after HCT in pediatric patients. Vitamin D Deficiency before HSCT was associated with increased rate of aGVHD in patients with thalassemia major. Higher tacrolimus pharmacokinetic variability had a greater risk of aGVHD that rose alongside concentration variability. defibrotide added to standard-of-care graft-versus-host disease prophylaxis appeared to improve the rate of acute GVHD. FEV1/FVC and PEF/pred could identify patients with higher risk for pulmonary chronic graft-versus-host disease before HSCT. Elaine DeMeyer describes cardiovascular toxicities related to GVHD and what nurses should look for to evaluate risk. Elaine DeMeyer, RN, MSN, describes cGVHD phenotypes presenting in the lungs, including BOS and COP. Real-world data showed that ruxolitinib was effective in a population of heavily pretreated patients with cGVHD. Vedolizumab was safe and effective for GI aGVHD treatment, although its efficacy as GVHD prophylaxis was unclear.